Effect of cost-free energy storage material and saline water depth on the performance of square pyramid solar still: a mathematical and experimental study

Journal of Thermal Analysis and Calorimetry - Low productivity of single-slope solar still is the main barrier for its worldwide usability. An attempt has been conducted to enhance the distillate...     

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss or inhibition of DNA repair proteins, such as poly(ADP-ribose) polymerase-1 (PARP-1). Inhibitors of nuclear PARPs are effective therapeutics for a number of different types of cancers. Here we review key concepts and current progress on the therapeutic use of PARP inhibitors (PARPi). PARPi selectively induce synthetic lethality in cancer cells with homologous recombination deficiencies (HRDs), the most notable being cancer cells harboring mutations in the BRCA1 and BRCA2 genes. Recent clinical evidence, however, shows that PARPi can be effective as cancer therapeutics regardless of BRCA1/2 or HRD status, suggesting that a broader population of patients might benefit from PARPi therapy. Currently, four PARPi have been approved by the Food and Drug Administration (FDA) for the treatment of advanced ovarian and breast cancer with deleterious BRCA mutations. Although PARPi have been shown to improve progression-free survival, cancer cells inevitably develop resistance, which poses a significant obstacle to the prolonged use of PARP inhibitors. For example, somatic BRCA1/2 reversion mutations are often identified in patients with BRCA1/2-mutated cancers after treatment with platinum-based therapy, causing restoration of HR capacity and thus conferring PARPi resistance. Accordingly, PARPi have been studied in combination with other targeted therapies to overcome PARPi resistance, enhance PARPi efficacy, and sensitize tumors to PARP inhibition. Moreover, multiple clinical trials are now actively underway to evaluate novel combinations of PARPi with other anticancer therapies for the treatment of PARPi-resistant cancer. In this review, we highlight the mechanisms of action of PARP inhibitors with or without BRCA1/2 defects and provide an overview of the ongoing clinical trials of PARPi. We also review the current progress on PARPi-based combination strategies and PARP inhibitor resistance.Subject terms: Cancer therapy, Mechanisms of disease, PolyADP-ribosylation     

Fast‐Geomimicking using Chemistry in Supercritical Water

Herein we introduce a powerful and fast method to produce nanominerals using a bottom up approach. The supercritical hydrothermal flow synthesis is exploited to produce model nanominerals by mimicking natural environments at high temperatures under pressure. This innovative concept is demonstrated with the talc synthesis; this represents a major technical breakthrough since it allows decreasing the mineral‐synthesis time from tens of hours to tens of seconds. Through this example, we show these nanominerals exhibit new crystal‐chemistry signals and new properties. This approach provides a means to reproduce the early stages of formation of minerals in different natural environments from sedimentary environments (low temperature and pressure) to hydrothermal/metamorphic environments (high temperature and high pressure).     

Studies of the association of chitosan and alkylated chitosan with oppositely charged sodium dodecyl sulfate

Cationic biopolymer chitosan has many applications in food, cosmetic and pharmaceutical industries. Grafting alkylated chains on its backbone can hydrophobically modify this water-soluble polymer.This paper concerns unmodified chitosan, alkylated chitosan and their interactions with a model anionic surfactant, sodium dodecyl sulfate (SDS). The solvent is pH 4 acetic acid solution. The purpose of this study is to highlight the hydrophobicity brought by the alkylated chains by comparing surface tension measurements and rheological properties of hydrophobically modified polymer (HMP) and chitosan solutions at 25 °C.Interactions of chitosan and HMP with surfactant have also been investigated giving information about surface activity and electrical conductivity of such systems. It results that alkylated chitosan/SDS system is more surface active than chitosan/SDS and it offers new potential applications in pharmaceutical and cosmetic fields because of the formation of amphiphilic complexes.     

2,5-Dimethylfuran Production by Catalytic Hydrogenation of 5-Hydroxymethylfurfural Using Ni Supported on Al2O3-TiO2-ZrO2 Prepared by Sol-Gel Method: The Effect of Hydrogen Donors

5-Hydroxymethylfurfural (5-HMF) has been described as one of the 12 key platform molecules derived from biomass by the US Department of Energy, and its hydrogenation reaction produces versatile liquid biofuels such as 2,5-dimethylfuran (2,5-DMF). Catalytic hydrogenation from 5-HMF to 2,5-DMF was thoroughly studied on the metal nickel catalysts supported on Al₂O₃-TiO₂-ZrO₂ (Ni/ATZ) mixed oxides using isopropanol and formic acid (FA) as hydrogen donors to find the best conditions of the reaction and hydrogen donor. The influence of metal content (wt%), Ni particle size (nm), Nickel Ni⁰, Ni⁰/NiO and NiO species, metal active sites and acid-based sites on the catalyst surface, and the effect of the hydrogen donor (isopropanol and formic acid) were systematically studied. The structural characteristics of the materials were studied using different physicochemical methods, including N₂ physisorption, XRD, Raman, DRS UV-Vis, FT-IR, SEM, FT-IR Py_ad, H₂-TPD, CO₂-TPD, H₂-TPR, TEM and XPS. Second-generation 2,5-DMF biofuel and 5-HMF conversion by-products were analyzed and elucidated using ¹H NMR. It was found that the Ni⁰NiO/ATZ3_WI catalyst synthesized by the impregnation method (WI) generated a good synergistic effect between the species, showing the best catalytic hydrogenation of 5-HMF to 2,5-DMF using formic acid as a hydrogen donor for 24 h of reaction and temperature of 210 °C with 20 bar pressure of Argon (Ar).